BioPharmSignal logoBioPharmSignal

Biotech News

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

Cogent Biosciences (COGT)Cogent BiosciencesEarnings

Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass.

Related news

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Cogent Biosciences

Genetically Defined Diseases Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2. Bezuclastinib Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT...

Recent company news

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

COGTCogent Biosciences2026-06-30 12:00 EST

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Stock data

Close
29.58 USD
Market cap
5.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States